Arsanis, Inc. Expands Its Anti-Infective Monoclonal Antibody Programs With Additional Grant Support From FFG and EUROSTARS
9/10/2012 9:16:14 AM
)--Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of two major grants for the development of monoclonal antibody therapeutics against nosocomial infections. Both grant supports involve the Austrian Research Promotion Agency (Österr. Forschungsförderungs GmbH or “FFG”), the leading public funding agency for applied research in Austria.